JENA, Germany, Aug. 21, 2025 — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company focused on developing anti-inflammatory drugs by targeting the complement system, announced today its participation in two investor conferences during September 2025. The details are provided below:
Cantor Global Healthcare Conference 2025
September 3 – 5, 2025, New York, NY
A fireside chat is scheduled for September 4th at 9:10 AM ET.
InflaRx will also hold one-on-one meetings with investors on September 4th. A link to watch the live stream and replay of the fireside chat is available.
H.C. Wainwright 27th Annual Global Investment Conference
September 8 – 10, 2025, New York, NY
A presentation is scheduled for September 9th at 3:30 PM ET.
InflaRx will also hold one-on-one meetings with investors on September 9th. A link to register for the live stream and replay of the presentation is available.
About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company that develops anti-inflammatory therapeutics by utilizing its proprietary anti-C5a and anti-C5a receptor technologies to discover, develop, and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor. C5a is a potent inflammatory mediator involved in the progression of various inflammatory diseases. InflaRx has developed vilobelimab, a first-in-class, intravenously administered, anti-C5a monoclonal antibody that selectively binds to free C5a and has shown disease-modifying clinical activity and tolerability in several clinical trials. InflaRx is also developing INF904, an orally administered small molecule inhibitor of C5a-induced signaling through the C5a receptor.
InflaRx was established in 2007 and maintains offices and subsidiaries in Jena and Munich, Germany, and Ann Arbor, MI, USA. Additional information is available at www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (collectively, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: |
Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. All statements that are not historical facts are forward-looking statements. These statements are often identified by words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential,” or “continue,” among others. These forward-looking statements appear throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations, and the risks, uncertainties, and other factors described in our periodic filings with the SEC under the headings “Risk factors” and “Cautionary statement regarding forward looking statements.” These statements are made as of the date of this press release and are subject to known and unknown risks, uncertainties, and other important factors that could cause our actual results, performance, or achievements to differ significantly from any future results, performance, or achievements expressed or implied by the forward-looking statements. Due to these risks, uncertainties, and other factors, you should not rely excessively on these forward-looking statements. We assume no obligation to update these statements, even if new information becomes available in the future, except as required by law.
“`
